Empirical study of treatment of peritoneal carcinomatosis with a combination of adenoviral p53 gene therapy and thymosin ?1
- VernacularTitle:腺病毒介导p53基因联合胸腺肽治疗腹腔转移癌的实验研究
- Author:
Ling HUANG
;
Xiaodong QI
;
Kaitong ZHANG
- Publication Type:Journal Article
- Keywords:
Peritoneal carcinomatosis;
Adenoviral;
p53 gene;
Thymosin
- From:
Cancer Research and Clinic
2006;0(10):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cooperative effect of intraperitoneal adenoviral p53 gene therapy together with thymosin ?1 against peritoneal carcinomatosis. Methods KM mouse model bearing peritoneal carcinomatosis was established using H22 cell line. 48 hours after inoculation, adenoviral-mediated p53 gene was administrated intraperitoneally alone, or combined with thymosin ?1 within 7 days. The abdominal girth, body weight, tumor cell number, apoptosis and cell cycle were tested using methods of cell counting and flow cytometry. Results Adenoviral p53 gene transfer alone arrested H22 cell in G0/G1. In combination therapy group, ascitic fluid was obviously halted, tumor cells in peritoneal cavity decreased in number and ascites formation, dead cell ratio was elevated. Conclusion Adenoviral-mediated p53 gene could block cell proliferation. Intraperitoneal adenoviral p53 gene therapy combined with thymosin ?1 showed synergism for the lethal damage and inhibition for peritoneal carcinomatosis.
